Avanos Medical (AVNS) posts Q1 2026 results and $1.272B AIP buyout deal
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Avanos Medical, Inc. reported first quarter 2026 results and highlighted a pending acquisition by affiliates of American Industrial Partners in an all-cash transaction valuing the company at an enterprise value of $1.272 billion.
For the quarter, net sales were $182.2 million, up 8.8% from $167.5 million a year earlier, driven by double-digit organic growth in the Specialty Nutrition Systems segment. Net income was $5.1 million versus $6.6 million last year, with diluted EPS of $0.11 compared to $0.14. Adjusted net income was $10.6 million and adjusted diluted EPS $0.22, down from $12.0 million and $0.26.
Specialty Nutrition Systems net sales rose to $124.0 million, while Pain Management & Recovery net sales were $56.3 million and roughly flat year over year, with that segment moving to an operating loss of $1.8 million. Adjusted EBITDA was stable at $21.8 million versus $21.6 million.
Cash used in operating activities was $12.3 million, compared with cash provided of $25.7 million in the prior-year quarter. Free cash flow was an outflow of $16.6 million versus an inflow of $19.0 million. Cash and cash equivalents were $65.6 million as of March 31, 2026, with total debt of $98.2 million on the term loan facility.
Positive
- Strong top-line growth and SNS performance: Net sales rose to $182.2 million, up 8.8% year over year, with Specialty Nutrition Systems net sales increasing to $124.0 million and delivering 22.7% growth and $23.1 million of operating income.
- Stable adjusted EBITDA: Adjusted EBITDA held essentially flat at $21.8 million versus $21.6 million in the prior-year quarter, indicating relatively steady operating earnings despite segment mix shifts.
- Transformative acquisition agreement: The company previously announced a definitive agreement to be acquired by affiliates of American Industrial Partners in an all-cash transaction at a stated enterprise value of $1.272 billion.
Negative
- Margin and earnings pressure: Net income declined to $5.1 million from $6.6 million, with diluted EPS falling to $0.11 from $0.14 and adjusted diluted EPS decreasing to $0.22 from $0.26 year over year.
- Weaker cash generation: Cash from operations swung to a $12.3 million use versus $25.7 million provided a year ago, and free cash flow moved from a $19.0 million inflow to a $16.6 million outflow.
- Pain Management & Recovery profitability deterioration: The PM&R segment’s net sales were roughly flat at $56.3 million, but it shifted from $0.2 million of operating income to a $1.8 million operating loss.
Insights
Solid revenue growth and strong nutrition segment contrast with weaker earnings and cash flow.
Avanos Medical grew Q1 2026 net sales to $182.2 million, up 8.8% year over year, led by its Specialty Nutrition Systems business, which delivered $124.0 million in net sales and 22.7% growth. This segment generated operating income of $23.1 million, or 18.6% of its net sales.
Despite growth, profitability softened. Company-wide net income declined to $5.1 million from $6.6 million, and adjusted diluted EPS fell from $0.26 to $0.22. The Pain Management & Recovery segment remained roughly flat in revenue at $56.3 million but swung from a small operating profit to a $1.8 million loss.
Cash generation weakened meaningfully. Cash used in operations was $12.3 million, compared with cash provided of $25.7 million in the prior-year quarter, and free cash flow moved to an outflow of $16.6 million. The company ended March 31, 2026 with $65.6 million in cash and $98.2 million in total debt. The previously announced all-cash acquisition agreement with American Industrial Partners at an enterprise value of $1.272 billion represents a major strategic milestone alongside these operating trends.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Net sales: $182.2 million
Net income: $5.1 million
Diluted EPS: $0.11
+5 more
8 metrics
Net sales
$182.2 million
Three months ended March 31, 2026; up 8.8% year over year
Net income
$5.1 million
Q1 2026 vs $6.6 million in Q1 2025
Diluted EPS
$0.11
Q1 2026; down from $0.14 in prior-year quarter
Adjusted diluted EPS
$0.22
Q1 2026; compared with $0.26 in Q1 2025
Adjusted EBITDA
$21.8 million
Q1 2026; near flat versus $21.6 million in Q1 2025
Free cash flow
-$16.6 million
Outflow in Q1 2026 vs $19.0 million inflow in Q1 2025
SNS segment net sales
$124.0 million
Specialty Nutrition Systems Q1 2026 net sales; 22.7% growth
AIP enterprise value
$1.272 billion
Enterprise value for pending all-cash acquisition by AIP
Key Terms
Adjusted EBITDA, free cash flow, enterprise value, Specialty Nutrition Systems, +2 more
6 terms
Adjusted EBITDA financial
"Adjusted EBITDA was $21.8 million, compared to $21.6 million a year ago."
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
free cash flow financial
"For the three months ended March 31, 2026, free cash flow was an outflow of $16.6 million, compared to an inflow of $19.0 million"
Free cash flow is the amount of money a company has left over after paying all its expenses and investing in its business, like buying equipment or updating facilities. It shows how much cash is available to reward shareholders, pay down debt, or save for future growth. This helps investors understand if a company is financially healthy and able to grow.
enterprise value financial
"in an all-cash offer at an enterprise value of $1.272 billion"
Enterprise value is the total worth of a company, reflecting what it would cost to buy the entire business. It includes the company's market value plus any debts, minus its cash holdings, offering a comprehensive picture of its true value. Investors use it to compare companies regardless of their capital structures, helping them assess how much they would need to pay to acquire the business.
Specialty Nutrition Systems financial
"The Specialty Nutrition Systems (“SNS”) segment delivered above-market results in the first quarter of 2026"
non-GAAP financial measures financial
"This press release and the accompanying tables include the following financial measures that have not been calculated in accordance with accounting principles generally accepted"
Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.
effective tax rate financial
"Effective tax rate 32.9 % ... 28.9 %"
The effective tax rate is the percentage of a company's profits that it pays in taxes. It shows how much of its earnings go to taxes after all deductions and credits are considered. For investors, it indicates how much of the company's income is taken by taxes, impacting overall profitability and financial health.
Earnings Snapshot
Net sales: $182.2 million
Q1 2026
Net sales
$182.2 million
+8.8% YoY
Net income
$5.1 million
down from $6.6 million
Diluted EPS
$0.11
down from $0.14
Adjusted diluted EPS
$0.22
down from $0.26
Adjusted EBITDA
$21.8 million
vs $21.6 million
Free cash flow
-$16.6 million
vs $19.0 million inflow
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 5, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||||||||
| (Address of principal executive offices) | (Zip code) | |||||||||||||||||||
Registrant’s telephone number, including area code: (844 ) 428-2667
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On May 5, 2026, Avanos Medical, Inc. issued a press release announcing its results of operations for the three months ended March 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.
The information contained in Item 2.02 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in Item 2.02 of this Current Report or Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits.
| Exhibit No. | Description | |||||||
99.1 | Press release issued by Avanos Medical, Inc. on May 5, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AVANOS MEDICAL, INC. | ||||||||||||||
| Date: | May 5, 2026 | By: | /s/ John J. Hurley | |||||||||||
| John J. Hurley Controller (Principal Accounting Officer) | ||||||||||||||
 | ||||||||
| Investor Contact: Scott Galovan | ||||||||
| Avanos Medical, Inc. | ||||||||
| Investor.Relations@Avanos.com | ||||||||
| Media Contact: Katrine Kubis | ||||||||
| Avanos Medical, Inc. | ||||||||
| CorporateCommunications@Avanos.com | ||||||||
Avanos Medical, Inc. Announces First Quarter 2026 Results
•Delivered double-digit organic growth led by Specialty Nutrition Systems segment
•Generated $0.11 of diluted earnings per share and $0.22 of adjusted diluted earnings per share
•On April 14, 2026, announced the execution of a definitive agreement to be acquired by certain affiliates of American Industrial Partners (“AIP”) in an all-cash offer at an enterprise value of $1.272 billion
ALPHARETTA, Ga., May 5, 2026/PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported first quarter 2026 financial results.
“Building off our strong 2025 results, we delivered solid first quarter performance led by double-digit organic revenue growth in our Specialty Nutrition Systems segment,” said David Pacitti, Avanos’ chief executive officer. Pacitti continued, “Our overall execution this quarter was positive, and I’m very pleased with the steady progress we’re making against each of our strategic imperatives.”
First Quarter 2026 Highlights
•Total net sales were $182.2 million, an 8.8% increase from the comparable prior year period.
•Net income was $5.1 million, compared to $6.6 million a year ago.
•Adjusted net income was $10.6 million, compared to $12.0 million a year ago.
•Diluted earnings per share was $0.11, compared to $0.14 a year ago.
•Adjusted diluted earnings per share was $0.22, compared to $0.26 a year ago.
•Adjusted EBITDA was $21.8 million, compared to $21.6 million a year ago.
Specialty Nutrition Systems Segment
•The Specialty Nutrition Systems (“SNS”) segment delivered above-market results in the first quarter of 2026, achieving net sales of $124.0 million, an increase of $22.9 million compared to the prior year period.
•Operating income in the SNS segment for the three months ended March 31, 2026 was $23.1 million, or 18.6% of SNS net sales, an increase of $2.0 million compared to the prior year period.
Pain Management & Recovery Segment
•Pain Management and Recovery (“PM&R”) segment net sales for the first quarter of 2026 were $56.3 million. Overall PM&R net sales growth was relatively flat compared to the prior year period.
•Operating loss in the PM&R segment for the first quarter of 2026 was $1.8 million compared to operating income of $0.2 million last year.
Cash Flow and Balance Sheet
Cash used in operations for the three months ended March 31, 2026 was $12.3 million, compared to cash flow from operations of $25.7 million a year ago. For the three months ended March 31, 2026, free cash flow was an outflow of $16.6 million, compared to an inflow of $19.0 million in the prior year.
As of March 31, 2026, the Company’s cash balance was $65.6 million compared to $97.0 million a year ago and $89.8 million as of December 31, 2025. Total debt at the end of the first quarter totaled $98.2 million, consisting of borrowings on the Company’s term loan facility.
Non-GAAP Financial Measures
This press release and the accompanying tables include the following financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S., or GAAP, and are therefore referred to as non-GAAP financial measures:
•Adjusted gross and operating income;
•Adjusted income before taxes;
•Adjusted effective tax rate;
•Adjusted net income;
•Adjusted diluted earnings per share;
•Adjusted selling, general and administrative expenses;
•Adjusted EBITDA; and
•Free cash flow.
These non-GAAP financial measures exclude the following items, as applicable, for the relevant time periods as indicated in the accompanying non-GAAP reconciliations to the comparable GAAP financial measures:
•Certain acquisition and integration charges related to acquisitions;
•Expenses associated with restructuring and transformation activities, including the divestiture of the Company’s respiratory health business;
•Expenses or recoveries associated with certain litigation matters;
•The amortization of intangible assets associated with business acquisitions;
•The tax effects of certain adjusting items; and
•The positive or negative effect of changes in currency exchange rates during the year.
The Company provides these non-GAAP financial measures as supplemental information to its GAAP financial measures. Management and the Company’s board of directors use net sales on a constant currency basis, adjusted net income, adjusted diluted earnings per share, adjusted operating income, adjusted EBITDA, and free cash flow to: (a) evaluate the Company’s historical and prospective financial performance and its performance relative to its competitors, (b) allocate resources, and (c) measure the operational performance of the Company’s business units and their managers. Management also believes that the use of an adjusted effective tax rate provides improved insight into the tax effects of the Company’s ongoing business operations.
Additionally, the Compensation Committee of the Company’s board of directors will use certain of the non-GAAP financial measures when setting and assessing achievement of incentive compensation goals. These goals are based, in part, on the Company’s net sales on a constant currency basis and adjusted EBITDA, which will be determined by excluding certain items that are used in calculating these non-GAAP financial measures.
Our competitors may define these non-GAAP financial measures differently, and as a result, our measure of these non-GAAP financial measures may not be directly comparable to those of other companies. Items excluded from these non-GAAP financial measures are significant components in understanding and assessing financial performance. These non-GAAP financial measures are supplemental measures of operating performance that do not represent, and should not be considered in isolation or as an alternative to, or substitute for, the financial statement data presented in the Company’s consolidated financial statements as indicators of financial performance. These non-GAAP financial measures have limitations as analytical tools, and should not be considered in isolation, or as a substitute for analysis of the Company’s results as reported under GAAP. We compensate for these limitations by relying primarily on our GAAP results and using these non-GAAP financial measures as supplemental information.
Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the attached financial tables.
About Avanos Medical, Inc.
Avanos Medical (NYSE: AVNS) is a medical technology company focused on delivering clinically superior solutions that will help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, Avanos is committed to addressing some of today’s most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands globally and holds leading market positions in multiple categories across its portfolio. For more information, visit www.avanos.com and follow Avanos Medical on X (@AvanosMedical), LinkedIn and Facebook.
Forward-Looking Statements
This press release contains information that includes or is based on “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by the use of words such as “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan” or “continue” and similar expressions. Forward-looking statements are based on the current plans and expectations of management and are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; our inability to complete our pending merger with certain affiliates of American Industrial Partners on the anticipated terms or timeline, or at all; potential adverse effects on our business and operations due to the pendency of the merger; shortage in drugs used in our Surgical Pain and Recovery products or other disruptions in our supply chain; the ongoing regional conflicts between Russia and Ukraine and in the Middle East; our ability to successfully execute on or achieve the expected benefits of our transformation initiative or our divestiture, acquisition or merger transactions; inflationary pressures; the expected impact of tariffs and our ability to mitigate tariffs; financial conditions affecting the banking system and the potential threats to the solvency of commercial banks; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the impact of investigative and legal proceedings and compliance risks; the impact of the federal legislation to reform the United States healthcare system; changes in financial markets; and changes in the competitive environment. The information contained herein speaks only as of the date of this release and we undertake no obligation to update forward-looking statements, except as may be required by the securities laws.
Additional information concerning these and other factors that may impact future results is contained in our filings with the U.S. Securities and Exchange Commission, including our most recent Form 10-Q.
AVANOS MEDICAL, INC.
CONDENSED CONSOLIDATED INCOME STATEMENTS
(unaudited)
(in millions, except per share amounts)
| Three Months Ended March 31, | |||||||||||
| 2026 | 2025 | ||||||||||
| Net Sales | $ | 182.2 | $ | 167.5 | |||||||
| Cost of products sold | 88.0 | 77.7 | |||||||||
| Gross Profit | 94.2 | 89.8 | |||||||||
| Research and development expenses | 5.2 | 5.4 | |||||||||
| Selling and general expenses | 77.7 | 75.7 | |||||||||
| Other expense (income), net | 2.4 | (1.6) | |||||||||
| Operating Income | 8.9 | 10.3 | |||||||||
| Interest income | 0.2 | 1.5 | |||||||||
| Interest expense | (1.5) | (2.1) | |||||||||
| Income before income taxes | 7.6 | 9.7 | |||||||||
| Income tax provision | (2.5) | (3.1) | |||||||||
| Net Income | $ | 5.1 | $ | 6.6 | |||||||
| Interest expense, net | $ | 1.3 | $ | 0.6 | |||||||
| Income tax provision | 2.5 | 3.1 | |||||||||
| Depreciation and amortization | 10.2 | 9.6 | |||||||||
| EBITDA | $ | 19.1 | $ | 19.9 | |||||||
| Earnings Per Share | |||||||||||
| Basic | $ | 0.11 | $ | 0.14 | |||||||
| Diluted | 0.11 | 0.14 | |||||||||
| Common Shares Outstanding | |||||||||||
| Basic | 46.5 | 46.1 | |||||||||
| Diluted | 47.5 | 46.7 | |||||||||
AVANOS MEDICAL, INC.
NON-GAAP RECONCILIATIONS
(unaudited)
(in millions, except per share amounts)
| Three Months Ended March 31, 2026 | |||||||||||||||||||||||||||||||||||
| As reported | Acquisition and Integration | Post-RH Divestiture Restructuring | Intangibles Amortization | Tax effects | As Adjusted Non-GAAP | ||||||||||||||||||||||||||||||
| Net Sales | $ | 182.2 | $ | — | $ | — | $ | — | $ | — | $ | 182.2 | |||||||||||||||||||||||
| Cost of products sold | 88.0 | — | (1.5) | (1.6) | — | 84.9 | |||||||||||||||||||||||||||||
| Gross Profit | 94.2 | — | 1.5 | 1.6 | — | 97.3 | |||||||||||||||||||||||||||||
| Gross Profit Margin | 51.7 | % | 53.4 | % | |||||||||||||||||||||||||||||||
| Research and development expenses | 5.2 | — | — | — | — | 5.2 | |||||||||||||||||||||||||||||
| Selling and general expenses | 77.7 | (0.4) | (0.3) | (3.0) | — | 74.0 | |||||||||||||||||||||||||||||
| SG&A as a percentage of Net Sales | 42.6 | % | 40.6 | % | |||||||||||||||||||||||||||||||
| Other expense, net | 2.4 | (0.5) | — | — | — | 1.9 | |||||||||||||||||||||||||||||
| Operating Income | 8.9 | 0.9 | 1.8 | 4.6 | — | 16.2 | |||||||||||||||||||||||||||||
| Interest income | 0.2 | — | — | — | — | 0.2 | |||||||||||||||||||||||||||||
| Interest expense | (1.5) | — | — | — | — | (1.5) | |||||||||||||||||||||||||||||
| Income before income taxes | 7.6 | 0.9 | 1.8 | 4.6 | — | 14.9 | |||||||||||||||||||||||||||||
| Income tax provision | (2.5) | — | — | — | (1.8) | (4.3) | |||||||||||||||||||||||||||||
| Effective tax rate | 32.9 | % | 28.9 | % | |||||||||||||||||||||||||||||||
| Net Income | $ | 5.1 | $ | 0.9 | $ | 1.8 | $ | 4.6 | $ | (1.8) | $ | 10.6 | |||||||||||||||||||||||
| Diluted Earnings Per Share | $ | 0.11 | $ | 0.22 | |||||||||||||||||||||||||||||||
AVANOS MEDICAL, INC.
NON-GAAP RECONCILIATIONS
(unaudited)
(in millions, except per share amounts)
| Three Months Ended March 31, 2025 | |||||||||||||||||||||||||||||||||||||||||
| As reported | Acquisition and Integration | Post-RH Divestiture Restructuring | Litigation and Legal | Intangibles Amortization | Tax effects | As Adjusted Non-GAAP | |||||||||||||||||||||||||||||||||||
| Net Sales | $ | 167.5 | $ | — | $ | — | $ | — | $ | — | $ | — | $ | 167.5 | |||||||||||||||||||||||||||
| Cost of products sold | 77.7 | — | (2.3) | — | (2.9) | — | 72.5 | ||||||||||||||||||||||||||||||||||
| Gross Profit | 89.8 | — | 2.3 | — | 2.9 | — | 95.0 | ||||||||||||||||||||||||||||||||||
| Gross Profit Margin | 53.6 | % | 56.7 | % | |||||||||||||||||||||||||||||||||||||
| Research and development expenses | 5.4 | — | — | — | — | — | 5.4 | ||||||||||||||||||||||||||||||||||
| Selling and general expenses | 75.7 | — | (0.8) | — | (2.2) | — | 72.7 | ||||||||||||||||||||||||||||||||||
| SG&A as a percentage of Net Sales | 45.2 | % | 43.4 | % | |||||||||||||||||||||||||||||||||||||
| Other income, net | (1.6) | — | — | 1.4 | — | — | (0.2) | ||||||||||||||||||||||||||||||||||
| Operating Income | 10.3 | — | 3.1 | (1.4) | 5.1 | — | 17.1 | ||||||||||||||||||||||||||||||||||
| Interest income | 1.5 | — | — | — | — | — | 1.5 | ||||||||||||||||||||||||||||||||||
| Interest expense | (2.1) | — | — | — | — | — | (2.1) | ||||||||||||||||||||||||||||||||||
| Income before income taxes | 9.7 | — | 3.1 | (1.4) | 5.1 | — | 16.5 | ||||||||||||||||||||||||||||||||||
| Income tax provision | (3.1) | — | — | — | — | (1.4) | (4.5) | ||||||||||||||||||||||||||||||||||
| Effective tax rate | 32.0 | % | 27.3 | % | |||||||||||||||||||||||||||||||||||||
| Net Income | $ | 6.6 | $ | — | $ | 3.1 | $ | (1.4) | $ | 5.1 | $ | (1.4) | $ | 12.0 | |||||||||||||||||||||||||||
| Diluted Earnings Per Share | $ | 0.14 | $ | 0.26 | |||||||||||||||||||||||||||||||||||||
AVANOS MEDICAL, INC.
NON-GAAP RECONCILIATIONS
(unaudited)
(in millions)
| EBITDA | |||||||||||
| Three Months Ended March 31, | |||||||||||
| 2026 | 2025 | ||||||||||
| Net income | $ | 5.1 | $ | 6.6 | |||||||
| Interest expense, net | 1.3 | 0.6 | |||||||||
| Income tax provision | 2.5 | 3.1 | |||||||||
| Depreciation | 5.6 | 4.5 | |||||||||
| Amortization | 4.6 | 5.1 | |||||||||
| EBITDA | 19.1 | 19.9 | |||||||||
| Acquisition and integration-related charges | 0.9 | — | |||||||||
| Post-RH Divestiture restructuring | 1.8 | 3.1 | |||||||||
| Litigation and legal | — | (1.4) | |||||||||
| Adjusted EBITDA | $ | 21.8 | $ | 21.6 | |||||||
AVANOS MEDICAL, INC.
NON-GAAP RECONCILIATIONS
(unaudited)
(in millions except per share amounts)
| Free Cash Flow | |||||||||||
| Three Months Ended March 31, | |||||||||||
| 2026 | 2025 | ||||||||||
| Cash (used in) provided by operating activities | $ | (12.3) | $ | 25.7 | |||||||
| Capital expenditures | (4.3) | (6.7) | |||||||||
| Free Cash Flow | $ | (16.6) | $ | 19.0 | |||||||
AVANOS MEDICAL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(in millions)
| March 31, 2026 | December 31, 2025 | ||||||||||
| ASSETS | |||||||||||
| Current Assets | |||||||||||
| Cash and cash equivalents | $ | 65.6 | $ | 89.8 | |||||||
| Accounts receivable, net | 103.0 | 103.8 | |||||||||
| Inventories | 141.3 | 148.0 | |||||||||
| Prepaid and other current assets | 15.1 | 13.8 | |||||||||
| Total Current Assets | 325.0 | 355.4 | |||||||||
| Property, Plant and Equipment, net | 111.2 | 113.4 | |||||||||
| Operating Lease Right-of-Use Assets | 39.3 | 27.6 | |||||||||
| Goodwill | 394.0 | 394.9 | |||||||||
| Other Intangible Assets, net | 114.7 | 117.8 | |||||||||
| Deferred Tax Assets | 33.0 | 33.1 | |||||||||
| Other Assets | 32.9 | 31.5 | |||||||||
| TOTAL ASSETS | $ | 1,050.1 | $ | 1,073.7 | |||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
| Current Liabilities | |||||||||||
| Current portion of long-term debt | $ | 10.9 | $ | 10.2 | |||||||
| Current portion of operating lease liabilities | 10.4 | 8.2 | |||||||||
| Trade accounts payable | 52.3 | 55.5 | |||||||||
| Accrued expenses | 57.6 | 91.3 | |||||||||
| Total Current Liabilities | 131.2 | 165.2 | |||||||||
| Long-Term Debt | 87.3 | 90.3 | |||||||||
| Operating Lease Liabilities | 29.8 | 20.4 | |||||||||
| Deferred Tax Liabilities | 5.6 | 6.1 | |||||||||
| Other Long-Term Liabilities | 14.1 | 13.5 | |||||||||
| TOTAL LIABILITIES | 268.0 | 295.5 | |||||||||
| Stockholders’ Equity | 782.1 | 778.2 | |||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 1,050.1 | $ | 1,073.7 | |||||||
AVANOS MEDICAL, INC.
CONDENSED CONSOLIDATED CASH FLOW STATEMENTS
(unaudited)
(in millions)
| Three Months Ended March 31, | |||||||||||
| 2026 | 2025 | ||||||||||
| Operating Activities | |||||||||||
| Net income | $ | 5.1 | $ | 6.6 | |||||||
| Depreciation and amortization | 10.2 | 9.6 | |||||||||
| Loss on asset dispositions | 0.1 | 0.2 | |||||||||
| Changes in operating assets and liabilities, net of acquisition | (32.4) | 5.4 | |||||||||
| Deferred income taxes and other | 4.7 | 3.9 | |||||||||
| Cash (Used in) Provided by Operating Activities | (12.3) | 25.7 | |||||||||
| Investing Activities | |||||||||||
| Capital expenditures | (4.3) | (6.7) | |||||||||
| Investment in non-affiliates | (3.4) | (2.4) | |||||||||
| Cash Used in Investing Activities | (7.7) | (9.1) | |||||||||
| Financing Activities | |||||||||||
| Secured debt repayments | (2.3) | (2.3) | |||||||||
| Revolving credit facility repayments | — | (25.0) | |||||||||
| Purchases of treasury stock | (1.3) | (2.2) | |||||||||
| Proceeds from the exercise of stock options | 0.4 | 0.4 | |||||||||
| Cash Used in Financing Activities | (3.2) | (29.1) | |||||||||
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | (1.0) | 1.8 | |||||||||
| Decrease in Cash and Cash Equivalents | (24.2) | (10.7) | |||||||||
| Cash and Cash Equivalents - Beginning of Period | 89.8 | 107.7 | |||||||||
| Cash and Cash Equivalents - End of Period | $ | 65.6 | $ | 97.0 | |||||||
AVANOS MEDICAL, INC.
SELECTED BUSINESS SEGMENT DATA
(unaudited)
(in millions)
| Three Months Ended March 31, | |||||||||||||||||||||||||||||
| 2026 | 2025 | Change | |||||||||||||||||||||||||||
| Specialty Nutrition Systems: | |||||||||||||||||||||||||||||
| Enteral feeding | $ | 84.6 | $ | 74.5 | 13.6 | % | |||||||||||||||||||||||
| Neonate solutions | 39.4 | 26.6 | 48.1 | % | |||||||||||||||||||||||||
| Total Specialty Nutrition Systems | 124.0 | 101.1 | 22.7 | % | |||||||||||||||||||||||||
| Pain Management & Recovery: | |||||||||||||||||||||||||||||
| Surgical pain and recovery | 21.8 | 24.5 | (11.0) | % | |||||||||||||||||||||||||
| Radiofrequency Ablation | 34.5 | 31.7 | 8.8 | % | |||||||||||||||||||||||||
| Total Pain Management & Recovery | 56.3 | 56.2 | 0.2 | % | |||||||||||||||||||||||||
| Corporate and Other | 1.9 | 10.2 | (81.4) | % | |||||||||||||||||||||||||
| Total Net Sales | $ | 182.2 | $ | 167.5 | 8.8 | % | |||||||||||||||||||||||
| Operating Income (Loss) | |||||||||||||||||||||||||||||
| Specialty Nutrition Systems | $ | 23.1 | $ | 21.1 | 9.5 | % | |||||||||||||||||||||||
| Pain Management & Recovery | (1.8) | 0.2 | N.M. | ||||||||||||||||||||||||||
| Corporate and Other | (12.4) | (11.0) | N.M. | ||||||||||||||||||||||||||
| Total Operating Income | $ | 8.9 | $ | 10.3 | N.M. | ||||||||||||||||||||||||
| Net sales - percentage change (YTD) | Total | Volume | Pricing/Mix | Currency | Other(a) | ||||||||||||||||||||||||
| Specialty Nutrition Systems | 22.7 | % | 19.0 | % | 1.4 | % | 2.8 | % | (0.5) | % | |||||||||||||||||||
| Pain Management & Recovery | 0.2 | % | 3.2 | % | 0.1 | % | 1.0 | % | (4.1) | % | |||||||||||||||||||
| Corporate and Other | (81.4) | % | (81.4) | % | — | % | — | % | — | % | |||||||||||||||||||
______________________________
N.M.: Not Meaningful
(a)Other includes the effects of our withdrawal from certain revenue streams that did not meet our return criteria and rounding.
FAQ
How did Avanos Medical (AVNS) perform in Q1 2026?
Avanos Medical grew Q1 2026 net sales to $182.2 million, up 8.8% year over year. However, net income fell to $5.1 million from $6.6 million, and diluted EPS declined to $0.11 from $0.14, reflecting margin and earnings pressure.
What were Avanos Medical’s key non-GAAP results for Q1 2026?
Avanos reported adjusted net income of $10.6 million, compared with $12.0 million a year earlier. Adjusted diluted EPS was $0.22 versus $0.26, and adjusted EBITDA was $21.8 million compared with $21.6 million, showing essentially flat adjusted operating earnings.
How did Avanos Medical’s business segments perform in Q1 2026?
The Specialty Nutrition Systems segment posted net sales of $124.0 million, up 22.7%, with operating income of $23.1 million. Pain Management & Recovery net sales were $56.3 million and roughly flat, but segment results moved to a $1.8 million operating loss.
What is Avanos Medical’s cash flow and balance sheet position after Q1 2026?
For Q1 2026, Avanos had cash used in operations of $12.3 million and free cash flow outflow of $16.6 million. As of March 31, 2026, the company held $65.6 million in cash and $98.2 million in total debt on its term loan.
What acquisition has Avanos Medical agreed to with American Industrial Partners?
On April 14, 2026, Avanos announced a definitive agreement to be acquired by certain affiliates of American Industrial Partners. The transaction is structured as an all-cash offer valuing the company at an enterprise value of $1.272 billion, subject to customary conditions.
Why does Avanos Medical use non-GAAP financial measures like adjusted EBITDA and free cash flow?
Avanos uses adjusted net income, adjusted EPS, adjusted EBITDA, and free cash flow to evaluate performance, allocate resources, and set incentive compensation goals. These measures exclude items such as acquisition charges, restructuring, litigation, and intangible amortization, with reconciliations provided to the nearest GAAP metrics.